Clinical applications of 18F-FDG PET in the management of hepatobiliary and pancreatic tumors

Abdominal Imaging

Volumn 37, Issue 6, 2012, Pages 983-1003

  De Gaetano, Anna Maria ^a   Rufini, Vittoria ^a   Castaldi, Paola ^a   Gatto, Anna Maria ^a   Filograna, Laura ^a   Giordano, Alessandro ^a   Bonomo, Lorenzo ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Cholangiocellular carcinoma; Hepatocellular carcinoma; Pancreatic cancer; Positron emission tomography

Indexed keywords

CARBON 11; FLUORINE 18; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BILIARY TRACT TUMOR; BODY HEIGHT; BODY MASS; BODY WEIGHT; BONE METASTASIS; BREATHING; CANCER PROGNOSIS; CANCER SURVIVAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TUMOR; LUNG METASTASIS; LYMPH NODE METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; OVERALL SURVIVAL; PANCREAS TUMOR; PET SCANNER; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TIME; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; ADENOCARCINOMA; BILE DUCT CARCINOMA; BILE DUCT TUMOR; COLORECTAL TUMOR; IMAGE PROCESSING; INTRAHEPATIC BILE DUCT; METASTASIS; PATHOLOGY; REVIEW; SCINTISCANNING;

ADENOCARCINOMA; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER NEOPLASMS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84878172968     PISSN: 09428925     EISSN: 14320509     Source Type: Journal    
DOI: 10.1007/s00261-012-9845-y     Document Type: Article

References (91)

1. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771-1777
2. Wahl RL (2004) Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 45:82S-95S
3. Delbeke D, Martin WH, Sandler MP, et al. (1998) Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 133(5):510-515
4. Zimmerman RL, Burke M, Young NA, Solomides CC, Bibbo M (2002) Diagnostic utility of Glut-1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration. Cancer 96(1):53-57
5. 18F]FDG-PET. J Nucl Med 36(10):1811-1817
6. Khan MA, Combs CS, Brunt EM, et al. (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32:792-797
7. Iwata Y, Shiomi S, Sasaki N, et al. (2000) Clinical usefulness of positron emission tomography scanning with fluorine- 18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med 14:121-126
8. 18F-FDG positron emission tomography for evaluation of hepatocellular carcinoma. Korean J Hepatol 12:546-552
9. Shiomi S, Nishiguchi S, Ishizu H, et al. (2001) Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 96:1877-1880
10. 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 31:1621-1630
11. Ho CL, Yu SC, Yeung DW (2003) [11C]-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44:213-221
12. Li S, Beheshti M, Peck-Radosavljevic M, et al. (2006) Comparison of (11) C-acetate positron emission tomography and (67) Gallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver Int 26:920-927
13. 18F]FDG PET/CT: A preliminary study. Appl Radiat Isot 67:1195-1198
14. 18F-FDG PET. J Nucl Med 49(8):1245-1248
15. Seo S, Hatano E, Higashi T, et al. (2007) Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 13:427-433
16. Kong YH, Han CJ, Lee SD, et al. (2004) Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma. Korean J Hepatol 10:279-287
17. Yang SH, Suh KS, Lee HW, et al. (2006) The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 12:1655-1660
18. 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver transplantation 16:767-772
19. 18F-FDG PET/CT. World J Hepatol 1(1):90-97
20. 18F-FDG PET/CT. J Nucl Med 51(12):1849-1856
21. Torizuka T, Tamaki N, Inokuma T, et al. (1994) Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 35:1965-1969
22. Chen YK, Hsieh DS, Liao CS, et al. (2005) Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res 25:4719-4725
23. Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H (2003) FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 28(3):192-197
24. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 39:961-968
25. Nagaoka S, Itano S, Ishibashi M, et al. (2006) Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int 26:781-788
26. Kawaoka T, Aikata H, Takaki S, et al. (2009) FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 39(2):134-142
27. Sun L, Guan YS, Pan WM, et al. (2007) Positron emission tomography/computer tomography in guidance of extrahepatic hepatocellular carcinoma metastasis management. World J Gastroenterol 13:5413-5415
28. Farley DR, Weaver AL, Nagorney DM (1995) ''Natural history'' of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 70:425-429
29. Jarnagin WR, Fong Y, DeMatteo RP, et al. (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507-517
30. Kluge R, Schmidt F, Caca K, et al. (2001) Positron emission tomography with [(18)F]fluoro-2-deoxy-d-glucose for diagnosis and staging of bile duct cancer. Hepatology 33(5):1029-1035
31. 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol 23:759-765
32. 18F- fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 206(1):57-65
33. Anderson CD, Rice MH, Pinson CW, et al. (2004) Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 8(1):90-97
34. Kato T, Tsukamoto E, Kuge Y, et al. (2002) Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 29(8):1047-1054
35. Fritscher-Ravens A, Bohuslavizki KH, Broering DC, et al. (2001) FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 22:1277-1285
36. Petrowsky H, Wildbrett P, Husarik DB, et al. (2006) Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 45(1):43-50
37. 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 103(5):1145-1151
38. 18F-FDG PET-CT. Rev Esp Med Nucl 28(2):74-77
39. Rodríguez-Fernández A, Gómez-Río M, Llamas-Elvira JM, et al. (2004) Positron-emission tomography with fluorine-18-fluoro-2-deoxy-d-glucose for gallbladder cancer diagnosis. Am J Surg 188(2):171-175
40. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. (1998) Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 206(3):755-760
41. Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ (2004) FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol 30(3):286-291
42. 18F]fluoro-2-deoxy-d-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 92(3):362-369
43. Huebner RH, Park KC, Shepherd JE, et al. (2000) A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 41(7):1177-1189
44. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF (2002) Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224(3):748-756
45. Bipat S, van Leeuwen MS, Comans EFI, et al. (2005) Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 237:123-131
46. Selzner M, Hany TF, Wildbrett P, et al. (2004) Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 240(6):1027-1034
47. Rappeport ED, Loft A, Berthelsen AK, et al. (2007) Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 48(4):369-378
48. Ramos E, Valls C, Martinez L, et al. (2011) Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT? Ann Surg Oncol 18:2654-2661
49. Vitola JV, Delbeke D, Sandler MP, et al. (1996) Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 171(1):21-26
50. Schüssler-Fiorenza CM, Mahvi DM, Niederhuber J, Rikkers LF, Weber SM (2004) Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J Gastrointest Surg 8(2):150-157
51. Purandare NC, Rangarajan V, Shah SA, et al. (2011) Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings. Radiographics 31(1):201-213
52. Whiteford MH, Whiteford HM, Ogunbiyi OA, et al. (2000) Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 43:759-770
53. Berger KL, Nicholson SA, Dehdashti F, Siegel BA (2000) FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR 174:1005-1008
54. Kubota R, Yamada S, Kubota K, et al. (1992) Intratumoral distribution of F18-fluoro-deoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by micro-autoradiography. J Nucl Med 33:1972-1980
55. Donadon M, Bona S, Montorsi M, Torzilli G (2010) FDG-PET positive granuloma of the liver mimicking local recurrence after hepatic resection of colorectal liver metastasis. Hepatogastroenterology 57(97):138-139
56. 18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 23(34):8713-8716
57. 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 50(Suppl 1):43S-54S
58. Wray CJ, Ahmad SA, Matthews JB, Lowy AM (2005) Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 128:1626-1641
59. Wagner M, Redaelli C, Lietz M, et al. (2004) Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 91:586-594
60. Reske SN, Grillenberger KG, Glatting G, et al. (1997) Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 38:1344-1348
61. Pakzad F, Groves AM, Ell PJ (2006) The role of positron emission tomography in the management of pancreatic cancer. Semin Nucl Med 36:248-256
62. Higashi T, Tamaki N, Torizuka T, et al. (1998) FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 39:1727-1735
63. 18F-fluorodeoxyglucose positron emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 20:109-116
64. Gambhir SS, Czernin J, Schwimmer J, et al. (2001) A tabulated summary of the FDG PET literature. J Nucl Med 42(suppl 5):1S-93S
65. 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging 35:1775-1785
66. 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 250:957-963
67. Bares R, Klever P, Hauptmann S, et al. (1994) F18-fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192:79-86
68. Zimny M, Bares R, Fass J, et al. (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24:678-682
69. Lytras D, Connor S, Bosonnet L, et al. (2005) Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer. Dig Surg 22:55-62
70. Inokuma T, Tamaki N, Torizuka T, et al. (1995) Evaluation of pancreatic tumors with positron emission tomography and F-18 18 fluorodeoxyglucose: comparison with CT and US. Radiology 195:345-352
71. Koyama K, Okamura T, Kawabe J, et al. (2001) Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 15:217-224
72. Bang S, Chung HW, Park SW, et al. (2006) The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 40:923-929
73. Serrano OK, Chaudhry MA, Leach SD (2010) The role of PET scanning in pancreatic cancer. Adv Surg 44:313-325
74. 18F- fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. World J Gastroenterol 17(2):231-235
75. 18F- fluorodeoxyglucose positron emission tomography to the diagnosis of early pancreatic carcinoma. J Hepatobiliary Pancreat Surg 15:634-639
76. 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions. Gastroenterol Clin Biol 34:465-474
77. Hong HS, Yun M, Cho A, et al. (2010) The utility of F18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm. Clin Nucl Med 35:776-779
78. Sperti C, Pasquali C, Decet G, et al. (2005) F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 9(1):22-28
79. 18F-FDG PET findings and GLUT-1 expression in IPMNs of the pancreas. J Nucl Med 49:2070
80. Sperti C, Bissoli S, Pasquali C, et al. (2007) 18-Fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 246:932-939
81. 18F]-fluoro-2-deoxy-d-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep 24(3):613-620
82. 18F-fluoro-2-deoxy-d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 32:389-397
83. 18F-FDG-PET/CT in the assessment of pancreatic cancer: is the contrast or a better-designed trial needed? J Gastroenterol Hepatol 26:613-618
84. 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer. World J Gastroenterol 14(1):64-69
85. 18F-FDG PET/CT: 1-stop-shop imaging for assessing the respectability of pancreatic cancer. J Nucl Med 49:1408-1413
86. Nishiyama Y, Yamamoto Y, Yokoe K, et al. (2005) Contribution of whole body FDG-PET to the detection of distant metastases in pancreatic cancer. Ann Nucl Med 19:491-497
87. Heinrich S, Goerres GW, Schafer M, et al. (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242:235-243
88. Frohlich A, Diederichs CG, Staib L, et al. (1999) Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 40:250-255
89. Kuwatani M, Kawakami H, Eto K, et al. (2009) Modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers. Intern Med 48:867-875
90. Maisey NR, Webb A, Flux GD, et al. (2000) FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 83(3):287-293
91. Ruf J, Lopez Hanninen E, Oettle H, et al. (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/RM. Pancreatology 5:266-272